Stem Cells International

Manufacturing Cells for Clinical Use


Status
Published

Lead Editor

1Kansas State University, Manhattan, USA

2Carpenter Group Consulting Inc., Washington, USA

3Athersys Inc, Cleveland, USA

4Justus Liebig University Giessen, Giessen, Germany


Manufacturing Cells for Clinical Use

Description

Over the past decade, cell therapy has moved forward on multiple fronts. For example, according to one report in 2014, 373 clinical trials worldwide use stem cell therapy (Bersenev Alexey. Cell therapy clinical trials – 2014 report. Cell Trials blog. January 22, 2015. Available: http://celltrials.info/2015/01/22/2014-report/). Most of these trials use mesenchymal stromal cells (116 in 2014, ibid) which require GMP grade manufacturing to produce cells of sufficient number and quality for a clinical product. Similarly, embryonic stem cells (3 trials in 2014, ibid) are in clinical trials. In the near future, induced pluripotent stem cells will provide patient-specific cells for clinical application. There are a number of considerations and regulatory requirements to move cellular therapy into the clinic. The field is rapidly evolving.

We invite reviews and original papers describing the current state of the art and the challenges along with potential solutions to be submitted for consideration in a special issue of Stem Cells International on Cell Manufacturing for Clinical use. Both experimental and applied papers are welcome.

Potential topics include, but are not limited to:

  • Manufacturing MSCs for clinical use
  • Use of bioreactors or other specialized equipment for cellular manufacturing
  • Characterization of cells for clinical use
  • Theoretical and applied scale-up of manufacturing processes for cellular therapy
  • Special manufacturing considerations such as gene modified cells
  • Regulatory considerations

Articles

  • Special Issue
  • - Volume 2016
  • - Article ID 1750697
  • - Editorial

Manufacturing Cells for Clinical Use

Mark L. Weiss | Mahendra S. Rao | ... | Peter Czermak
  • Special Issue
  • - Volume 2016
  • - Article ID 3764681
  • - Review Article

Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells

Nadine E. Rekittke | Meidjie Ang | ... | Thomas Linn
  • Special Issue
  • - Volume 2016
  • - Article ID 5246584
  • - Research Article

Attachment, Growth, and Detachment of Human Mesenchymal Stem Cells in a Chemically Defined Medium

Denise Salzig | Jasmin Leber | ... | Peter Czermak
  • Special Issue
  • - Volume 2016
  • - Article ID 4760414
  • - Research Article

Theoretical and Practical Issues That Are Relevant When Scaling Up hMSC Microcarrier Production Processes

Valentin Jossen | Cedric Schirmer | ... | Dieter Eibl
  • Special Issue
  • - Volume 2016
  • - Article ID 6810980
  • - Research Article

Standardizing Umbilical Cord Mesenchymal Stromal Cells for Translation to Clinical Use: Selection of GMP-Compliant Medium and a Simplified Isolation Method

J. Robert Smith | Kyle Pfeifer | ... | Mark L. Weiss
  • Special Issue
  • - Volume 2016
  • - Article ID 3274054
  • - Research Article

Evaluation of Tissue Homogenization to Support the Generation of GMP-Compliant Mesenchymal Stromal Cells from the Umbilical Cord

Ryan J. Emnett | Aparna Kaul | ... | Salem Akel
  • Special Issue
  • - Volume 2016
  • - Article ID 7060975
  • - Review Article

Stem Cell Therapy for Treatment of Stress Urinary Incontinence: The Current Status and Challenges

Shukui Zhou | Kaile Zhang | ... | Qiang Fu
  • Special Issue
  • - Volume 2016
  • - Article ID 4078215
  • - Clinical Study

Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children

José Eugenio Vázquez Meraz | José Arellano-Galindo | ... | Elva Jiménez-Hernández
Stem Cells International
 Journal metrics
Acceptance rate44%
Submission to final decision76 days
Acceptance to publication35 days
CiteScore7.200
Impact Factor3.869
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.